|
|||||
|
|
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized,double‐blind,placebo‐controlled phase III trial with a 34‐week active‐controlled extension |
|
| Authors: | A. H. Barnett S. Patel R. Harper R. Toorawa S. Thiemann M. von Eynatten H.‐J. Woerle |
| Affiliation: | 1. Diabetes Centre, Heart of England NHS Foundation Trust and University of Birmingham, , Birmingham, UK;2. Boehringer Ingelheim, , Bracknell, UK;3. Boehringer Ingelheim, , Ingelheim, Germany |
| Abstract: | |
| Keywords: | DPP‐4 inhibitor glycaemic control incretin therapy metformin phase III study type 2 diabetes |